News Releases

RNS Number : 0411W MaxCyte, Inc. 07 December 2023     MaxCyte, Inc. (" MaxCyte " or the "Company")   Exercise of options and PDMR dealing   ROCKVILLE, MD , December 7, 2023 :   MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
Dec 07, 2023
RNS Number : 4853V MaxCyte, Inc. 04 December 2023     MaxCyte, Inc. (" MaxCyte " or the "Company")   Exercise of options and PDMR dealing   ROCKVILLE, MD , December 4, 2023 :   MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
Dec 04, 2023
ROCKVILLE, Maryland - 1 December 2023: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, announces that pursuant to its block admission facility, since 31 October 2023 it has issued 133,442 of common stock, $0.01 par, of the Company ("Common Stock") in satisfaction of the exercise of share options.
Dec 01, 2023
ROCKVILLE, MD, November 30, 2023: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovative, cell-based research, announces that on 27 November 2023, as per a filing lodged with the U.S. Securities and Exchange Commission, John Johnston, a Non-Executive Director of the Company, exercised options over 5,000 shares of common stock of $0.01 of the Company ("Common Stock") ("Exercise") in aggregate.
Nov 30, 2023
ROCKVILLE, MD, November 17, 2023: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovative, cell-based research, announces that on 14 November 2023, as per a filing lodged with the U.S. Securities and Exchange Commission, John Johnston, a Non-Executive Director of the Company, exercised options over 10,000 shares of common stock of $0.01 of the Company ("Common Stock") ("Exercise") in aggregate.
Nov 17, 2023
RNS Number : 7079T MaxCyte, Inc. 16 November 2023       MaxCyte Joins the Alliance for mRNA Medicines (AMM) as a Founding Member   MaxCyte continues supporting the advancement of novel therapeutics and looks to support education and advancement of mRNA medicines.
Nov 16, 2023
RNS Number : 8538S MaxCyte, Inc. 09 November 2023         MaxCyte announces filing of Form 10-Q for the quarterly period ended September 30, 2023   ROCKVILLE, MD , November 9, 2023   - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
Nov 09, 2023
RNS Number : 8496S MaxCyte, Inc. 09 November 2023           MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance   ROCKVILLE, MD , November 9, 2023   Ñ MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing
Nov 09, 2023